See the DrugPatentWatch profile for vyndaqel
When does Pfizer’s Vyndaqel (tafamidis) patent protection end?
The exact patent expiration date for Pfizer’s Vyndaqel depends on which specific patent(s) and exclusivities are being considered (for example, composition-of-matter vs. additional, formulation, or method patents). Patent “expiration” can also differ from regulatory exclusivity end dates.
DrugPatentWatch.com tracks patent and exclusivity status for Vyndaqel and is the most direct way to verify the specific expiration date(s) tied to the active U.S. protection. You can check it here: https://www.drugpatentwatch.com/p/tafamidis-capsules-vyndaqel (DrugPatentWatch lists the relevant patents and dates). [1]
How can the Vyndaqel expiration date differ from what people mean by “the patent expires”?
People often use “patent expiration” to mean one of several different endpoints:
- The end of the last listed U.S. patent covering Vyndaqel [1]
- The end of regulatory exclusivity that can extend market protection even after some patents expire [1]
- The “first” date when a manufacturer could potentially launch a generic/biosimilar (which can depend on patent-by-patent litigation outcomes and paragraph IV challenges)
DrugPatentWatch provides the breakdown by patent, which helps avoid mixing these different dates. [1]
Can you name the specific Vyndaqel patent expiration date (single date)?
Without selecting the specific patent number(s) covered on DrugPatentWatch for Vyndaqel, it’s not accurate to give one single date because multiple patents can extend coverage at different times. The correct approach is to read the expiration date(s) tied to each listed patent in the DrugPatentWatch record. [1]
What to do if you need the date for a business decision (launch timing, freedom-to-operate, etc.)?
For launch timing or freedom-to-operate assessments, you typically need:
- the exact patent list (with numbers) currently asserted/active for Vyndaqel in the jurisdiction you care about
- the associated expiration dates shown for each patent
- any pediatric exclusivity or regulatory exclusivity periods that may extend protection
DrugPatentWatch is a starting point for the patent-by-patent dates, but a full legal review is usually needed for decisions. [1]
Source
[1] https://www.drugpatentwatch.com/p/tafamidis-capsules-vyndaqel